Memphasys Strengthens Financial Flexibility While Advancing Commercialisation
Memphasys Limited (ASX: MEM) is an Australian reproductive biotechnology company focused on commercialising its patented Felix™ System for assisted reproductive technologies. The company recently extended the maturity of its existing convertible notes with long-term shareholder Peters Investments to 30 June 2026, improving balance sheet flexibility without altering the principal amount or conversion terms. The amendment also introduces a structured schedule for repayment of accrued interest, supporting disciplined cash flow management.
This extension aligns with Memphasys’ broader execution strategy as it advances key commercial and regulatory milestones. During 2025, the company achieved CE Mark approval for the Felix™ System and entered multiple commercial agreements across Europe and India, alongside receiving early commercial orders. Felix™ offers a faster, gentler and standardised alternative to traditional sperm centrifugation by reducing cellular stress and DNA damage. Looking ahead, 2026 is expected to build on recent momentum, with Memphasys targeting scaled production, margin improvement and broader global adoption of Felix™ as a new standard in sperm preparation.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au
x
Daily Dose of Buy, Sell & Hold recommendations before the market opens.
Start Your 7 Days Free Trial Now!
We use cookies to help us improve, promote, and protect our services. By continuing to use this site, we assume you consent to this. Read our Privacy Policy and Terms & Conditions
Memphasys Strengthens Financial Flexibility While Advancing Commercialisation
Memphasys Limited (ASX: MEM) is an Australian reproductive biotechnology company focused on commercialising its patented Felix™ System for assisted reproductive technologies. The company recently extended the maturity of its existing convertible notes with long-term shareholder Peters Investments to 30 June 2026, improving balance sheet flexibility without altering the principal amount or conversion terms. The amendment also introduces a structured schedule for repayment of accrued interest, supporting disciplined cash flow management.
This extension aligns with Memphasys’ broader execution strategy as it advances key commercial and regulatory milestones. During 2025, the company achieved CE Mark approval for the Felix™ System and entered multiple commercial agreements across Europe and India, alongside receiving early commercial orders. Felix™ offers a faster, gentler and standardised alternative to traditional sperm centrifugation by reducing cellular stress and DNA damage. Looking ahead, 2026 is expected to build on recent momentum, with Memphasys targeting scaled production, margin improvement and broader global adoption of Felix™ as a new standard in sperm preparation.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au